<DOC>
	<DOCNO>NCT00526305</DOCNO>
	<brief_summary>Due ALL Ph+ patient receive different treatment , propose therapeutical protocol : intensification treatment induction increment CR rate , allogenic transplantation first CR , autologous transplantation follow alfa interferon patient do allogenic transplantation .</brief_summary>
	<brief_title>LAL-Ph-2000 : Treatment Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive</brief_title>
	<detailed_description>Remission Induction : - Vincristine ( VCR ) : 1,5 mg/m2 i.v. , day 1 8 - Daunorubicin ( DNR ) : 60 mg/m2 i.v. , day 1 8 . - Prednisone ( PDN ) : 60 mg/m2/day , i.v . p.o. , day 1 14 - L-asparaginase ( L-ASA ) : 10.000 UI/m2 , i.v.days 5-7 11-13 Results : 1 . Standard response : The induction treatment complete drug , change L-ASA ARA-C , two week 2 Slow response . Chemotherapy mitoxantrone high dose ARA-C Intrathecal chemotherapy : Treatment mitoxantrone , ARA-C e hydrocortisone , day 1 22 CONSOLIDATION TREATMENT 1 Start two week last dose induction chemotherapy : - Mercaptopurine ( MP ) 50 mg/m2 , p.o. , day 1-7 , 28-35 56-63 - Mitoxantrone ( MTX ) : 3g/m2 , i.v. , 24 hour , day 1 , 28 56 . - VM-26 : 150 mg/m2 every 12 horas , i.v . ( infusión 1 hora ) , días 14 42 - ARA-C : 500 mg/m2 cada 12 hour , i.v. , 3 hour , day 14-15 42-43 - Intrathecal treatment , day 28 56 . 6.4 . CONSOLIDATION TREATMENT 2 Start week last dose mercaptopurine previous cycle - Dexamethasone ( DXM ) : - 10 mg/m2 day , p.o . i.v . day 1-14 - 5 mg/m2 day , p.o . i.v. , day 15-21 - Vincristine ( VCR ) : 1,5 mg/m2 i.v. , day 1 8 15 - Daunorubicin ( DNR ) : 30 mg/m2 i.v. , day 1 , 2 , 8 9 . - CFM 600 mg/m2 day , i.v. , day 1 15 - L-asparaginase ( L-ASA ) : 10.000 UI/m2 , i.v.or im , day 1-3 15-17 - Intrathecal treatment day 1 15 . TRANSPLANTATION Hematopoietic autologous transplantation relate donor , one two month last dose consolidation treatment . Hematopoietic autologous transplantation unrelated donor , patient young 45 , PS 0-1 Hematopoietic autologous transplantation patient without related donor without unrelated donor six month search</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>ALL BCR/ABL+ patient Age &lt; 65 year No previous treatment 1 . Other LLA variability 2 . Previous history coronary valvular , hypertensive cardiopathy illness 3 . Chronic hepatic illness 4 . Chronic respiratory insufficiency 5 . Renal insufficiency cause LLA 6 . Severe neurological problem cause LLA 7 . Severe affection performance status ( grade 34 OMS gradation ) cause LLA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Chromosome Philadelphia positive</keyword>
</DOC>